Novel immunomodulators for topical skin disease therapy

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The use of topical corticosteroids has revolutionised the treatment of inflammatory skin diseases. However, problems including pharmacological resistance, as well as the side effect profile of potent topical corticosteroids, has prompted studies to investigate into other topical non-corticosteroidal agents in inflammatory skin diseases. This review outlines the major types of inflammatory skin diseases and discusses emerging therapies based on topical immunosuppressive macrolide antibiotics. In particular, tacrolimus and ascomycin derivatives have been shown to be effective for treating atopic dermatitis with a surprising lack of side effects. It is expected that these agents will play an important role in future dermatological therapy. Accumulating evidence suggests the importance of lipid-derived mediators of inflammation (eicosanoids and platelet-activating factor) in cutaneous inflammatory diseases. The role of these mediators in skin inflammation is also addressed in this review. Though there appears to be a large amount of redundancy in the activities of these lipid mediators, this family of agents could potentially serve as targets for anti-inflammatory therapy. Inasmuch as the phospholipase A2 family of enzymes serve to synthesise both eicosanoids and platelet-activating factor, inhibition at this step could have important therapeutic benefits in designing therapy for inflammatory skin diseases.

Original languageEnglish
Pages (from-to)529-542
Number of pages14
JournalExpert Opinion on Investigational Drugs
Volume9
Issue number3
StatePublished - 2000

Fingerprint

Immunologic Factors
Skin Diseases
Eicosanoids
Platelet Activating Factor
Adrenal Cortex Hormones
Lipids
Therapeutics
Inflammation Mediators
Phospholipases A2
Macrolides
Tacrolimus
Atopic Dermatitis
Immunosuppressive Agents
Anti-Inflammatory Agents
Pharmacology
Anti-Bacterial Agents
Inflammation
Skin
Enzymes

Keywords

  • ABT-281
  • Arachidonic acid
  • Atopic dermatitis
  • Clinical trials
  • Corticosteroids
  • Cyclooxygenase
  • Cyclosporin
  • Eicosanoids
  • ICI-204 219
  • Lipoxygenase
  • Phospholipase A
  • Platelet-activating factor
  • Psoriasis
  • SDM ASM 281-240
  • SDM ASM 981
  • Tacrolimus
  • Zileuton

ASJC Scopus subject areas

  • Pharmacology

Cite this

Novel immunomodulators for topical skin disease therapy. / Travers, Jeffrey.

In: Expert Opinion on Investigational Drugs, Vol. 9, No. 3, 2000, p. 529-542.

Research output: Contribution to journalArticle

@article{f4145222b2bc41fa9b8eda5b4614d20c,
title = "Novel immunomodulators for topical skin disease therapy",
abstract = "The use of topical corticosteroids has revolutionised the treatment of inflammatory skin diseases. However, problems including pharmacological resistance, as well as the side effect profile of potent topical corticosteroids, has prompted studies to investigate into other topical non-corticosteroidal agents in inflammatory skin diseases. This review outlines the major types of inflammatory skin diseases and discusses emerging therapies based on topical immunosuppressive macrolide antibiotics. In particular, tacrolimus and ascomycin derivatives have been shown to be effective for treating atopic dermatitis with a surprising lack of side effects. It is expected that these agents will play an important role in future dermatological therapy. Accumulating evidence suggests the importance of lipid-derived mediators of inflammation (eicosanoids and platelet-activating factor) in cutaneous inflammatory diseases. The role of these mediators in skin inflammation is also addressed in this review. Though there appears to be a large amount of redundancy in the activities of these lipid mediators, this family of agents could potentially serve as targets for anti-inflammatory therapy. Inasmuch as the phospholipase A2 family of enzymes serve to synthesise both eicosanoids and platelet-activating factor, inhibition at this step could have important therapeutic benefits in designing therapy for inflammatory skin diseases.",
keywords = "ABT-281, Arachidonic acid, Atopic dermatitis, Clinical trials, Corticosteroids, Cyclooxygenase, Cyclosporin, Eicosanoids, ICI-204 219, Lipoxygenase, Phospholipase A, Platelet-activating factor, Psoriasis, SDM ASM 281-240, SDM ASM 981, Tacrolimus, Zileuton",
author = "Jeffrey Travers",
year = "2000",
language = "English",
volume = "9",
pages = "529--542",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Novel immunomodulators for topical skin disease therapy

AU - Travers, Jeffrey

PY - 2000

Y1 - 2000

N2 - The use of topical corticosteroids has revolutionised the treatment of inflammatory skin diseases. However, problems including pharmacological resistance, as well as the side effect profile of potent topical corticosteroids, has prompted studies to investigate into other topical non-corticosteroidal agents in inflammatory skin diseases. This review outlines the major types of inflammatory skin diseases and discusses emerging therapies based on topical immunosuppressive macrolide antibiotics. In particular, tacrolimus and ascomycin derivatives have been shown to be effective for treating atopic dermatitis with a surprising lack of side effects. It is expected that these agents will play an important role in future dermatological therapy. Accumulating evidence suggests the importance of lipid-derived mediators of inflammation (eicosanoids and platelet-activating factor) in cutaneous inflammatory diseases. The role of these mediators in skin inflammation is also addressed in this review. Though there appears to be a large amount of redundancy in the activities of these lipid mediators, this family of agents could potentially serve as targets for anti-inflammatory therapy. Inasmuch as the phospholipase A2 family of enzymes serve to synthesise both eicosanoids and platelet-activating factor, inhibition at this step could have important therapeutic benefits in designing therapy for inflammatory skin diseases.

AB - The use of topical corticosteroids has revolutionised the treatment of inflammatory skin diseases. However, problems including pharmacological resistance, as well as the side effect profile of potent topical corticosteroids, has prompted studies to investigate into other topical non-corticosteroidal agents in inflammatory skin diseases. This review outlines the major types of inflammatory skin diseases and discusses emerging therapies based on topical immunosuppressive macrolide antibiotics. In particular, tacrolimus and ascomycin derivatives have been shown to be effective for treating atopic dermatitis with a surprising lack of side effects. It is expected that these agents will play an important role in future dermatological therapy. Accumulating evidence suggests the importance of lipid-derived mediators of inflammation (eicosanoids and platelet-activating factor) in cutaneous inflammatory diseases. The role of these mediators in skin inflammation is also addressed in this review. Though there appears to be a large amount of redundancy in the activities of these lipid mediators, this family of agents could potentially serve as targets for anti-inflammatory therapy. Inasmuch as the phospholipase A2 family of enzymes serve to synthesise both eicosanoids and platelet-activating factor, inhibition at this step could have important therapeutic benefits in designing therapy for inflammatory skin diseases.

KW - ABT-281

KW - Arachidonic acid

KW - Atopic dermatitis

KW - Clinical trials

KW - Corticosteroids

KW - Cyclooxygenase

KW - Cyclosporin

KW - Eicosanoids

KW - ICI-204 219

KW - Lipoxygenase

KW - Phospholipase A

KW - Platelet-activating factor

KW - Psoriasis

KW - SDM ASM 281-240

KW - SDM ASM 981

KW - Tacrolimus

KW - Zileuton

UR - http://www.scopus.com/inward/record.url?scp=0033993542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033993542&partnerID=8YFLogxK

M3 - Article

C2 - 11060693

AN - SCOPUS:0033993542

VL - 9

SP - 529

EP - 542

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 3

ER -